

Hypertrophic Cardiomyopathy (HCM)



Hypertrophic cardiomyopathy (HCM) is very common in cats, with the worst affected cats developing life-threatening complications. As median survival in cats with HCM and congestive heart failure (CHF) is only around 6 months, (J Payne et al, JSAP 2010) there is a real need for studies evaluating additional treatments to improve the morbidity, quality of life and long-term survival time in these cats.

The Royal Veterinary College in conjunction with an animal health company is conducting a study into the effects of a novel therapeutic agent on disease progression and potential clinical effectiveness in cats with HCM and CHF.

The study will run over a 6 month period for each cat. Cats eligible for this study must have a diagnosis of CHF within 1 month prior to enrolment. They must be at least 1 year of age and weigh 2kg or greater. Cats will not be eligible if they have clinical signs of ATE (aortic thromboembolism) or any other systemic diseases such as hyperthyroidism or diabetes mellitus.

Benefits for Clients include:

Free consultation, blood tests, radiographs, echocardiography and ECG (electrocardiogram) that are carried out in relation to the study

All trial medication is free of charge.

Benefits for the Veterinarian referring a cat, which is included in the study:

£100 CPD voucher or a copy of the BSAVA Manual of Canine and Feline Cardiorespiratory Medicine.

For the Practice which refers 3 cats that are included in the study:

Free Doppler blood pressure monitor.

RVC
**Royal
Veterinary
College**
University of London

To find out more contact:

The Clinical Investigation Centre

Tel: 01707 666605 Email: cic@rvc.ac.uk

Web: rvc.ac.uk/cic